Abstract
In the treatment of uncomplicated urinary tract infec-tions the following groups of antimicrobial are of clinical use: fluoroquinolones, trimethoprim/sulfamethoxazole, nitrofurantoin, fosfomycin (one dose). In uncomplicated acute cystitis the short 3 days courses of antimicrobials are preferred. Short courses have the number of advan-tages such as: the lower selective pressure on antimi-crobial resistance, lower rates of adverse reactions, high compliance and lower cost of treatment. But only few groups of antimicrobials could be used in short courses: fluoroquinolones, trimethoprim/sulfamethoxazole, nitro-furantoin, and fosfomycin with the last one available for one dose therapy. During last decade fosfomycin is a drug of particular interest for the treatment of UTI due to emerging and spreading of resistance in E. coli to fluo-roquinolones and trimethoprim/sulfamethoxazole. At the same time resistance to fosfomycin is rare with 0–1.5% of uropathogenic E. coli strains non-susceptible in different regions of Russia.
-
1.
Лопаткин Н.А., Деревянко И.И. Неосложненные и осложненные инфекции мочеполовых путей. Принципы антибактериальной терапии. РМЖ 1997; 24:1579-88.
-
2.
Страчунский Л.С., Рафальский В.В., Сехин С.В., Абрарова Э.Р. Практические подходы к выбору антибиотиков при неосложненных инфекциях мочевыводящих путей. Урология 2002; (2):8-14.
-
3.
Моисеев С.В Практические рекомендации по антибактериальной терапии и профилактике инфекций мочевыводящих путей с позиций доказательной медицины. Инфекции и антимикробная терапия 2003; (5):89-92.
-
4.
Naber K.G. Optimal management of uncomplicated and complicated urinary tract infections. Adv Clin Exp Med 1998; 7:41-6.
-
5.
Hooton T.M., Scholes D., Hughes J. et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 1996; 335:468-74.
-
6.
Лоран О.Б. Инфекции мочевыводящих путей амбулаторных больных: Материалы симпозиума., М., 1999; С.5-9.
-
7.
Mathew E., Gorbach S.L. Practice guidelines: urinary tract infections. Infect Dis Clin Pract 1995; 4:241-54.
-
8.
Hooton T.M., Stamm W.E. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997; 11:551-81.
-
9.
Рафальский В.В. Обоснование выбора антимикробных препаратов при амбулаторных инфекциях мочевыводящих путей. Дисс. д-ра мед. наук. Смоленск; 2004.
-
10.
Bailey R.R. Quinolones in the treatment of uncomplicated urinary tract infections. Int J Antimicrob Agents 1992; 2;19-28.
-
11.
Durier J.L. Anti-anaerobic antibiotic use in chronic inflammation, urgency, frequency, urge-incontinence and in interstitial cystitis. Interstitial Cystitis symposium, National Institutes of Health, Bethesda, 1995. р. 112
-
12.
Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health 1990; 80:331-3.
-
13.
Naber K.G. Short-term therapy of acute uncomplicated cystitis. Curr Opin Urol 1999; 9:57-64.
-
14.
Перепанова Т.С. Инфекции почек и мочевыводящих путей: современные подходы к терапии. Фарматека 2004; (3/4):16-22.
-
15.
Nicolle L. Empirical treatment of acute cystitis in women. Int J Antimicrob Agents 2003; 22:1-6.
-
16.
Skerk V., Krehen I., Schutnwald S. Antimicrobal therapy of urinary tract infections. Lijec Vjesn 2001; 123:16-25.
-
17.
Рафальский В.В., Страчунский Л.С., Кречикова О.И., Эйдельштейн И.А., и др. Оптимизация антимикробной терапии амбулаторных инфекций мочевыводящих путей по данным многоцентровых микробиологических исследований UTIAP-I, UTIAP-II. Урология 2004; (4):13-7.
-
18.
Uncomplicated UTIS in adults. E.A.U. Guidelines on urinary tract and male genital tract infections. p. 9-14.
-
19.
Bishop M.C. Uncomplicated urinary tract infection. EAU Updated Series 2004; 2:143-50.
-
20.
Shrestha N.K., Tomford J.W. Fosfomycin: a review. Infect Dis Clin Pract 2001; 10:255-60.
-
21.
Perri M.B., Hershberger E., Ionescu M., et al. In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis 2002; 42:269-71.
-
22.
Kahan F.M., Kahan J.S., Cassidy P.J., Kropp H. The mechanism of action fosfomycin (phosphonomycin). Ann N Y Acad Sci 1974; 235:364-86.
-
23.
Carlone N.A., Borsotto M., Cuffini A.M., Savoia D. Effect of fosfonomycin trometamol on bacterial adhesion in comparison with other chemotherapetic agents. Eur Urol 1987; 13(Suppl. 1):86-91.
-
24.
Albini E., Arena E., Belluco G., Marca G. Adhesion of bacteria to human uroepithelial cells and bactericidal activity of fosfonomycin trometamol. New Trends in Urinary Tract Infection. Int. Symp. Rome, 1987; p. 250-4.
-
25.
Zhanel G.G., Nicolle L.E. Effect of subinhibitory antimicrobial concentrations (sub-MICs) on in vitro bacterial adherence to uroepithelial cells. J Antimicrob Chemother 1992; 29:617-27.
-
26.
Аляев Ю.Г., Винаров А.З., Воскобойников В.Б. Острый цистит: этиология, клиника, лечение. Лечащий врач 2002; 4.
-
27.
Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO-SENS Project. J Antimicrob Chemother 2003; 51:69-76.
-
28.
Daza R., Gutierrez J., Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with communityacquired urinary tract infections. Int J Antimicrob Agents 2001; 18:211-5.
-
29.
Лоран О.Б., Страчунский Л.С., Рафальский В.В., Синякова Л.А., Косова И.В., Шевелев А.Н. Микробиологическая характеристика и клиническая эффективность фосфомицина. Урология 2004; (3):18-21.
-
30.
Lecome F. Le traitement monodose de la cystite par fosfomycine trometalor (Monuil): analyse de 15 essais compfrftis portent sur 2048 malades. Med Mal Infect 1996; 26:338-43.
-
31.
Maisonet M. Multicenter European study on continuous surveillance of nosocomial infections. Data for three years. Part III: Years 1990-1992. Collective publication of the pilot hospitals group of the international association for research in hospital hygiene.
-
32.
Ungheri D., Albini E., Belluco G. In vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol. J Chemother 2002; 14:237-40.
-
33.
Okazaki M., Suzuki K., Asano N., et al. Effectiveness of fosfomycin combined with other antimicrobial agents multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J Infect Chemother 2002; 8:37-42.
-
34.
Kumon H. Management of biofilm infections in the urinary tract. World J Surg 2000; 24:1193-6.
-
35.
Синякова Л.А., Косова И.В. Применение фосфомицина-трометамола (Монурала 3г) в лечении рецидивирующих инфекций мочевыводящих путей. ХII Российский национальный конгресс «Человек и лекарство»: Тезисы докладов; 2005 .